• Policy
• BMS’ Camzyos and Handok’s Empaveli pass the DREC review
• by Lee, Tak-Sun Jul 9, 2024 05:51am

• Policy
• Reassessing the comparison of foreign drug pricing is 'idle'
• by Lee, Tak-Sun Jul 8, 2024 05:46am

• Company
• HCV testing added to the National Health Screening Program
• by Hwang, Byung-woo Jul 8, 2024 05:46am

• Company
• New PNH drugs introduced into AstraZeneca’s reign
• by Son, Hyung-Min Jul 8, 2024 05:45am

• Company
• K-Bio receives FDA Orphan Drug Designations with novel drugs
• by Son, Hyung-Min Jul 8, 2024 05:45am

• Company
• Roche Korea starts reimb process for Columvi in Korea
• by Eo, Yun-Ho Jul 8, 2024 05:45am

• InterView
• “Prolia demonstrated a long-term treatment effect"
• by Son, Hyung-Min Jul 5, 2024 05:49am

• Company
• "Allowing switching between atopic dermatitis treatments"
• by Hwang, Byung-woo Jul 5, 2024 05:49am

• Company
• HLB ‘FDA meeting complete...no supplement data required'
• by Son, Hyung-Min Jul 5, 2024 05:48am

• Company
• New strength Uptravi may be prescribed at general hospitals
• by Eo, Yun-Ho Jul 5, 2024 05:48am